Log Out Log Out

In a severe hypoglycemia emergency

Ready for rescue

The first and only glucagon with nasal administration

BAQSIMITM is indicated for the treatment of severe hypoglycemic reactions which may occur in the management of insulin treated patients with diabetes mellitus, when impaired consciousness precludes oral carbohydrates.

Formulation invented in Canada

Baqsimi: Designed with serve hypoglycemia treatment in mind

  • Dry powder form of glucagon
  • Single use, pre-filled nasal device containing a 3 mg dose
  • Ready to use with no reconstitution or priming required
  • Does not need to be refrigerated
    • Can be stored up to 30°C (86°F) in the shrink-wrapped tube provided
  • Absorbed passively via the intranasal route—no inhalation required
  • BAQSIMI has a shelf life of 2 years from the date of manufacture
  • Each BAQSIMI device contains a single dose and is available as a 1-pack.
  • Efficacy +

    BAQSIMI began raising mean plasma glucose as early as 5 minutes*

    Mean plasma glucose concentrations over time with BAQSIMI

    * A randomized, multicenter, crossover noninferiority trial was conducted in adult patients with Type 1 diabetes. Hypoglycemia was induced with intravenous insulin and treated by 3 mg intranasal glucagon or 1 mg intramuscular glucagon. Plasma glucose was measured after each treatment was given.

    Nasally administered BAQSIMI demonstrated comparable efficacy to glucagon for injection in adult patients with Type 1 diabetes

    Treatment success for BAQSIMI and glucagon for injection*

    Treatment success was defined as the percentage of patients with either an increase in blood glucose to ≥3.9 mmol/L or an increase of ≥1.1 mmol/L from blood glucose nadir within 30 minutes.

    Nadir is defined as minimum glucose measurement at the time of or within 10 minutes after glucagon administration. The mean nadir blood glucose was 2.5 mmol/L for BAQSIMI and 2.7 mmol/L for injectable glucagon.

    Nasal congestion does not impact the absorption of BAQSIMI

    * Study IGBC was a randomized, multicenter, open-label, 2-period, crossover study in adult patients with Type 1 diabetes (n=77) that compared the efficacy of a single 3 mg dose of BAQSIMI versus 1 mg injectable glucagon for treatment of hypoglycemia induced by intravenous insulin with a target blood glucose of <2.8 mmol/L. The primary efficacy measure was the proportion of patients achieving treatment success.


    Click here to download the full study publication
  • Adult Safety+

    Baqsimi adverse Reactions in adult patients

    Adverse reactions (%) in adult Type 1 and Type 2 diabetes patients with an incidence ≥5%

    IGBC
    Type 1 and Type 2 diabetes
    Adverse Reactions BAQSIMI 3 mg
    (n=83) %
    INJECTABLE GLUCAGON 1 mg
    (n=82) %
    Eye disorders
    Lacrimation increased 8.4 1.2
    Gastrointestinal disorders
    Nausea 21.7 26.8
    Vomiting 15.7 11.0
    General disorders and administration site conditions
    Fatigue 8.4 8.5
    Nervous system disorders
    Headache 20.5 8.5
    Respiratory, thoracic, and mediastinal disorders
    Nasal discomfort 9.6 0
    Nasal congestion 8.4 1.2

Please note this link will take you to a website which is not part of LillyPro.ca.

Are you sure you want to
logout ?